Rasagiline – a novel MAO B inhibitor in Parkinson’s disease therapy

References

• Abu-RayaSBlaugrundETrembovlerVRasagiline, a novel MAO B inhibitor with neuroprotective effects under ischemic conditions in PC12 cellsDrug Dev Res20005028590
   Web of Science ®Google Scholar
• Abu-RayaSTabakmanRBlaugrundENeuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cellsEur J Pharmacol20024341091611779573
   PubMed Web of Science ®Google Scholar
• BiglanKMSchwidSEberlySRasagiline improves quality of life in patients with early Parkinson’s diseaseMov Disord2006216162316450340
   PubMed Web of Science ®Google Scholar
• BonuccelliUDel DottoPNew pharmacologic horizons in the treatment of Parkinson diseaseNeurology200667S30817030738
   PubMed Web of Science ®Google Scholar
• BraakHDel TrediciKRubUStaging of brain pathology related to sporadic Parkinson’s diseaseNeurobiol Aging20032419721112498954
   PubMed Web of Science ®Google Scholar
• ChenJJLyAVRasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson’s diseaseAm J Health Syst Pharm2006639152816675649
   PubMed Web of Science ®Google Scholar
• DawsonTMDawsonVLMolecular pathways of neurodegeneration in Parkinson’s diseaseScience20033028192214593166
   PubMed Web of Science ®Google Scholar
• ElmerLSchwidSEberlySRasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptomsJ Neurol Sci2006248788316828804
   PubMed Web of Science ®Google Scholar
• FDACenter for Drug Evaluation and Research [online]2006 Accessed 18 December 2006. URL: http://www.fda.gov/cder/foi/label/2006/021641lbl.pdf.
   Google Scholar
• GillmanPKMonoamine oxidase inhibitors, opioid analgesics and serotonin toxicityBr J Anaesth2005954344116051647
   PubMed Web of Science ®Google Scholar
• HartmannAHunotSMichelPPCaspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson’s diseaseProc Natl Acad Sci U S A20009728758010688892
   PubMed Web of Science ®Google Scholar
• HoffmanAStepenskyDPharmacodynamic aspects of modes of drug administration for optimization of drug therapyCrit Rev Ther Drug Carrier Syst19991657163910677802
   PubMed Web of Science ®Google Scholar
• HoffmanAStepenskyDLavyEPharmacokinetic and pharmacodynamic aspects of gastroretentive dosage formsInt J Pharm20042771415315158977
   PubMed Web of Science ®Google Scholar
• KlausnerEALavyEBartaMNovel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on levodopa absorption in humansPharm Res20032014667314567643
   PubMed Web of Science ®Google Scholar
• KupschASautterJGotzMEMonoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegilineJ Neural Transm2001108985100911716151
   PubMed Web of Science ®Google Scholar
• LandriganPJSonawaneBButlerRNEarly environmental origins of neurodegenerative disease in later lifeEnviron Health Perspect20051131230316140633
   PubMed Web of Science ®Google Scholar
• Leegwater-KimJWatersCTolcapone in the management of Parkinson’s diseaseExpert Opin Pharmacother2006722637017059382
   PubMed Web of Science ®Google Scholar
• LevyYSGilgun-SherkiYMelamedETherapeutic potential of neurotrophic factors in neurodegenerative diseasesBioDrugs2005199712715807629
   PubMed Web of Science ®Google Scholar
• MartiMMelaFFantinMBlockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson’s diseaseJ Neurosci200525959160116237164
   PubMed Web of Science ®Google Scholar
• McGeerPLMcGeerEGInflammation and neurodegeneration in Parkinson’s diseaseParkinsonism Relat Disord200410Suppl 1S3715109580
   PubMed Web of Science ®Google Scholar
• OlanowCWJankovicJNeuroprotective therapy in Parkinson’s disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategyMov Disord200520Suppl 11S31015822111
   PubMed Web of Science ®Google Scholar
• Parkinson study groupA controlled trial of rasagiline in early Parkinson disease: the TEMPO StudyArch Neurol20025919374312470183
   PubMed Web of Science ®Google Scholar
• Parkinson study groupA controlled, randomized, delayed-start study of rasagiline in early Parkinson diseaseArch Neurol200461561615096406
   PubMed Web of Science ®Google Scholar
• Parkinson study groupA randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO studyArch Neurol200562241815710852
   PubMed Web of Science ®Google Scholar
• RabeyJMSagiIHubermanMRasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson’s disease: a double-blind study as adjunctive therapy to levodopaClin Neuropharmacol2000233243011575866
   PubMed Web of Science ®Google Scholar
• RadadKGilleGRauschWDShort review on dopamine agonists: insight into clinical and research studies relevant to Parkinson’s diseasePharmacol Rep2005577011216382188
   PubMed Web of Science ®Google Scholar
• RascolOBrooksDJMelamedERasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomized, double-blind, parallel-group trialLancet20053659475415766996
   PubMed Web of Science ®Google Scholar
• RodriguezMCObesoJAOlanowCWSubthalamic nucleus-mediated excitotoxicity in Parkinson’s disease: a target for neuroprotectionAnn Neurol199844S175889749591
   PubMed Web of Science ®Google Scholar
• SpeiserZLevyRCohenSEffects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disordersJ Neural Transm Suppl1998522873009564629
   PubMedGoogle Scholar
• SternMBMarekKLFriedmanJDouble-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson’s disease patientsMov Disord2004199162315300656
   PubMed Web of Science ®Google Scholar
• StocchiFRasagiline: defining the role of a novel therapy in the treatment of Parkinson’s diseaseInt J Clin Pract2006602152116451296
   PubMed Web of Science ®Google Scholar
• SzetoHHMitochondria-targeted peptide antioxidants: novel neuro-protective agentsAAPS J20068E5213117025271
   PubMed Web of Science ®Google Scholar
• TabakmanRLechtSLazaroviciPNeuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson’s disease?Bioessays200426809014696044
   PubMed Web of Science ®Google Scholar
• TattonNAIncreased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson’s diseaseExp Neurol2000166294311031081
   PubMed Web of Science ®Google Scholar
• TattonWGChalmers-RedmanRBrownDApoptosis in Parkinson’s disease: signals for neuronal degradationAnn Neurol200353Suppl 3S6170 discussion S70–212666099
   PubMed Web of Science ®Google Scholar
• ThanviBLoNRobinsonTVascular parkinsonism – an important cause of parkinsonism in older peopleAge Ageing200534114915713855
   PubMed Web of Science ®Google Scholar
• ThebaultJJGuillaumeMLevyRTolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitorPharmacotherapy200424129530515628826
   PubMed Web of Science ®Google Scholar
• WuSSFruchtSJTreatment of Parkinson’s disease: what’s on the horizon?CNS Drugs2005197234316142989
   PubMed Web of Science ®Google Scholar